0.00
-6.83%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Axim Biotechnologies
From its filings with the US Securities and Exchange Commission
Axim Biotechnologies is based in San Diego, California and is incorporated in Nevada. Its shares trade on OTC under the ticker AXIM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $39,518 and a net loss of $8.1m. At that date it held total assets of $4.1m and shareholders' equity of −$7.7m.
Axim Biotechnologies, Inc., a Nevada corporation, is a leading developer of diagnostic healthcare solutions serving to enhance the health of people. Through the development of diagnostic solutions that quickly and accurately diagnose various diseases, our products allow healthcare workers to quickly test and treat at the point-of-care, which leads to improved patient outcomes and provides numerous economic benefits to the healthcare system.
Following the acquisition of two FDA cleared 510(k) tests for dye eye disease, the Company’s product focus has been primarily in the area of Eye Health. We continue to maintain the products and assays developed in connection with SARS-CoV-2 neutralizing antibody tests should a commercialization opportunity present itself in the future.
We were originally incorporated in the State of Nevada on November 18, 2010, under the name AXIM International, Inc. On July 24, 2014, we changed our name to AXIM Biotechnologies, Inc.
The Company’s historical business operations focused on the research, development and production of pharmaceutical, nutraceutical and cosmetic products based upon our proprietary technologies. This business and its related intellectual property were divested by the Company in May, 2020.
Quoted from its 10-K, filed 16 Apr 2024. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Apr 2013
- Employees
- 1
- Website
- aximbiotech.com ↗
- Head office
- 6191 CORNERSTONE COURT, E, SAN DIEGO, CA, 92121
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Catalina ValenciaPresident, Director$187,500
- Mr. Robert MalasekChief Financial Officer, Company Secretary$590,000
- Mr. Kurt PhinneyChief Operating Officer
- Mr. Peter O'RourkeDirector$20,000
- Mr. Blake SchroederDirector$20,000
- Mr. Robert CunninghamIndependent Director$20,000
- Dr. Timothy ScottIndependent Director$20,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Intellectual Property (IP) portfolio: Axim Biotechnologies Inc holds valuable patents and trademarks, providing a competitive advantage in the biotechnology industry.
- Innovative product pipeline: The company has a range of innovative products under development, which positions Axim Biotechnologies as a potential leader in various areas of healthcare and therapeutics.
- Strategic partnerships: Axim Biotechnologies has established collaborations with reputable organizations, leveraging their expertise and resources to drive research, development, and commercialization efforts.
Weaknesses
- Limited financial resources: Axim Biotechnologies may face funding constraints for R&D activities, potentially hindering the pace of product development and go-to-market strategies.
- Regulatory challenges: The biotechnology industry is subject to stringent regulations and compliance requirements, which can pose obstacles and delays in obtaining necessary approvals for product commercialization.
- Reliance on key personnel: The success of Axim Biotechnologies heavily depends on the expertise and experience of key individuals within the organization. The departure or unavailability of such personnel could impact operations and decision-making.
Opportunities
- Growing market demand: With an aging population and increasing focus on healthcare, Axim Biotechnologies can capitalize on the rising demand for innovative and effective medical solutions.
- Expansion into new markets: The company can explore untapped markets and geographic regions, expanding its footprint and diversifying revenue streams.
- Advancements in technology and research: Axim Biotechnologies can leverage technological advancements and breakthroughs in the field of biotechnology to enhance its product offerings and stay ahead of competitors.
Threats
- Intense competition: The biotechnology sector is highly competitive, with numerous players vying for market share. Axim Biotechnologies must continually innovate and differentiate its products to remain competitive.
- Market volatility and uncertainty: Economic fluctuations, regulatory changes, and market dynamics can impact Axim Biotechnologies' financial performance and investor confidence.
- Potential legal and intellectual property disputes: There is a risk of facing legal challenges or infringements regarding patents and intellectual property rights, which could result in significant costs and reputational damage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.